Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Juvenile Diabetes Research Foundation (JDRF) has agreed to support Selecta Biosciences to develop its vaccine technology which is intended to be used for the development of vaccines targeting type 1 diabetes.
Subscribe to our email newsletter
Under a research agreement signed between the two parties, JDRF is responsible to give milestone-based financial help to Selecta with an aim to use Selecta’s technology for the prevention and treatment of type 1 diabetes.
Selecta’s vaccine technology would ultimately be applied to create a therapeutic that would halt or prevent the autoimmune response that causes type 1 diabetes.
Selecta president and CEO Werner Cautreels said this collaboration accelerates their progress to apply Selecta’s novel vaccine technology to address the significant unmet medical needs in autoimmune diseases including type 1 diabetes.
JDRF Strategic Alliances senior vice president Karin Hehenberger said pooling the resources and strengths of both JDRF and Selecta allows them to work together to advance research that could help many people who have or are at risk for type 1 diabetes, and they will be more effective in making these products available to them.